Evidence that histamine is involved as a mediator of endothelium-dependent contraction induced by A23187 in bovine intrapulmonary vein.
This study was initiated to test the hypothesis that histamine can act as an endothelium-derived contracting factor in bovine isolated intrapulmonary vein. The effects of calcium ionophore, calcimycin (A23187), on isometric tension were compared in unstimulated rings of intrapulmonary vein with and without endothelium. A23187 (0.1-10 microM) induced concentration-related contraction when endothelium was present. Destruction of endothelium markedly inhibited A23187-induced contraction. Methylene blue, hemoglobin or NG-methyl-L-arginine significantly enhanced A23187-induced contraction only in venous rings with endothelium consistent with attenuation of the contraction by the concomitant release of endothelium-derived relaxing factor (nitric oxide) [EDRF(NO)]. Histamine H1 receptor antagonists inhibited, and iproniazid enhanced, contraction elicited by A23187. A23187 induced release of greater amounts of histamine from venous rings with than without endothelium. A23187-induced contraction was not mimicked by the mast cell activator, compound 48/80, and was not inhibited by preexposure to compound 48/80 or in the presence of cromolyn or doxantrazole. A23187-induced contraction was not inhibited by pretreatment with indomethacin, phentolamine, lipoxygenase inhibitors or superoxide dismutase. The results indicate that A23187 induces endothelium-dependent contraction in bovine intrapulmonary vein and support histamine as one major mediator involved. The association of destruction of endothelium with an inhibition of both A23187-induced contraction and histamine release is consistent with the endothelium as a source for histamine which can exert a local vasoconstrictor effect in bovine intrapulmonary vein.
Gruetter
C A
CA
Department of Pharmacology, Marshall University School of Medicine, Huntington, WV 25755-9310.
Lemke
S M
SM
Valentovic
M A
MA
Szarek
J L
JL
D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives / Q000494:pharmacology; D001285:Atropine / Q000494:pharmacology; D000001:Calcimycin / Q000494:pharmacology*; D002417:Cattle; D004205:Cromolyn Sodium / Q000494:pharmacology; D016232:Endothelins / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000502:physiology*; D006454:Hemoglobins / Q000494:pharmacology; D006632:Histamine / Q000502:physiology*; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D006636:Histamine Release / Q000187:drug effects; D066298:In Vitro Techniques; D007490:Iproniazid / Q000494:pharmacology; D008751:Methylene Blue / Q000494:pharmacology; D009119:Muscle Contraction / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects* / Q000502:physiology; D011667:Pulmonary Veins / Q000187:drug effects*; D013892:Thioxanthenes / Q000494:pharmacology; D044004:Xanthones; D019323:omega-N-Methylarginine; D003189:p-Methoxy-N-methylphenethylamine / Q000494:pharmacology
D016232:Endothelins; D006454:Hemoglobins; D006634:Histamine H1 Antagonists; D013892:Thioxanthenes; D044004:Xanthones; D019323:omega-N-Methylarginine; D000001:Calcimycin; D003189:p-Methoxy-N-methylphenethylamine; D001285:Atropine; D006632:Histamine; D001120:Arginine; D007490:Iproniazid; D004205:Cromolyn Sodium; D008751:Methylene Blue; C010134:doxantrazole